参考文献/References:
[1]Ye L,Wang J,Chen Q,et al. LCZ696,a promising novel agent in treating hypertension (a mata-analysis of randomized controlled trials)[J]. Oncotarget,2017,8(64):107991-108005.
[2]Cheung DG,Aizenberg D,Gorbunov V,et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan:a randomized,double-blind,8-week study[J]. J Clin Hypertens (Greenwich),2018,20(1):150-158.
[3]Huo Y,Li W,Webb R,et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension:a randomized,double‐blind,8‐week study[J]. J Clin Hypertens (Greenwich),2019,21(1):67-76.
[4]Supasyndh O,Sun N,Kario K,et al. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension[J].?Hypertens Res,2017,40(5):472-476.
[5]Schmieder RE,Wagner F,Mayr M,et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension:the results of a randomized,double-blind,active-controlled study[J]. Eur Heart J,2017,38(44):3308-3317.
[6]Chang AR, Holly K, Wei G, et al. Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT[J]. Clin J Am Soc Nephrol,2020, 15(8):1121-1128.
[7]Solomon SD, Rizkala AR, Lefkowitz MP, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial[J]. 2018,11(7):e004962.
[8]Ruilope LM,Dukat A,B?hm M,et al. Blood-pressure reduction with LCZ696,a novel dual-acting inhibitor of the angiotensinⅡreceptor and neprilysin:a randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet 2010, 375(9722):1255-1266.
[9]Kario K,Tamaki Y,Okino N,et al. LCZ696,a First-in-class angiotensin receptor-neprilysin inhibitor:the first clinical experience in patients with severe hypertension[J]. J Clin Hypertens (Greenwich),2016,18(4):308-314.
[10]Supasyndh O,Wang J,Hafeez K,et al. Efficacy and safety of sacubitril/valsartan(LCZ696) compared with olmesartan in elderly asian patients(≥65 years) with systolic hypertension[J]. Am J Hypertens,2017,30(12):1163‐1169.
[11]Williams B,Cockcroft JR,Kario K,et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension:the PARAMETER study[J]. Hypertension,2017,69(3):411-420.
[12]Wang TD,Tan RS,Lee HY,et al. Effects of sacubitril/valsartan(LCZ696) on natriuresis,diuresis,blood pressures,and NT-proBNP in salt-sensitive hypertension[J]. Hypertension,2017,69(1):32-41.
[13]Ito S,Satoh M,Tamaki Y,et al. Safety and efficacy of LCZ696,a first-in-class angiotensin receptor neprilysin inhibitor,in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res,2015,38(4):269-275.
[14]Kaplinsky E. After having changed the treatment of heart failure with reduced ejection fraction:what are the latest evidences with sacubitril valsartan?[J].?J Geriatr Cardiol,2019,16(2):151-155.
[15]Packer M,Claggett B,Lefkowitz MP,et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system:a secondary analysis of the PARADIGM-HF trial[J]. Lancet Diabetes Endocrinol,2018,6(7):547-554.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(2):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(2):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(2):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(2):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(2):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(2):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]程家元 殷跃辉.沙库巴曲缬沙坦在心血管疾病中的临床应用与展望[J].心血管病学进展,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
CHENG Jiayuan YIN Yuehui.Clinical Application and Prospect of Sacubitril Valsartan in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(2):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]